PLPaul D. Ling

Paul D. Ling

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Paul D. Ling has a total of 95 co-authors. Here are the top co-authors by number of shared publications:

  • Jie Tan

    Affiliation Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, United States of America

    11 shared publications
  • Gary S. Hayward

    Viral Oncology Program, Johns Hopkins School of Medicine

    7 shared publications
  • Rongsheng Peng

    Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA

    7 shared publications
  • Jie Tan

    Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA

    6 shared publications
  • RongSheng Peng

    Department of Molecular Virology and Microbiology, Baylor College of Medicine

    5 shared publications
  • Angela Fuery

    Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA

    4 shared publications

Latest Publications

  • Open Access

    First evidence of clinical protection from an EEHV1A mRNA vaccine in naturally infected juvenile elephants

    by Michael Wenninger, Lauren Farris, Jessica Heinz, RongSheng Peng, Gary S. Hayward, Jessica Watts, Jeroen Pollet, Jenny Nollman, Paul D. Ling

    Juvenile Asian elephants who have lost maternal antibodies are particularly susceptible to fatal hemorrhagic disease caused by primary infection with elephant endotheliotropic herpesvirus 1A (EEHV1A). To address this vulnerability, a multi-antigen EEHV1A mRNA vaccine has been administered to EEHV1A seronegative calves at four institutions. However, the extent to which this vaccine confers protective immunity remains an open question. In November 2023, two juvenile male calves (aged 6 and 7 years) were transferred from Dublin Zoo to the Cincinnati Zoo and Botanical Garden and confirmed to be seronegative for EEHV1A. Both calves received an experimental EEHV1A mRNA vaccine in October 2024, followed by a booster dose in November. Post-vaccination serological responses were robust, with significant antibody production against vaccine-encoded glycoproteins (gB, gH, gL, and gO), although titers started to decline by day 102 post-booster. In February 2025, the younger calf developed EEHV1A viremia, followed by the older calf in March. Both maintained viral loads below 6,000 viral genome equivalents (VGE)/mL and exhibited no hematological abnormalities or clinical signs of disease. Serum collected post-viremia revealed sustained antibody titers against the four vaccine antigens, approaching levels observed in naturally infected elephants. Despite confirmed viremia, both calves remained clinically healthy, and viral loads resolved without therapeutic intervention. These findings suggest that immunity generated against the EEHV proteins encoding the conserved herpesvirus attachment fusion complex can confer protective immunity and mitigate disease severity following primary infection in juvenile elephants. IMPORTANCE: This study delivers an early demonstration of applying mRNA vaccination to a herpesvirus outside conventional laboratory models and, to our knowledge, the first such use in an endangered mammalian species. EEHV-HD is the leading cause of death in juvenile Asian elephants, a species critical to global biodiversity and cultural heritage. Our findings provide both immunological evidence and real-world clinical protection, marking a significant advancement in wildlife health and expanding the translational potential of mRNA platforms beyond human medicine. These studies address an urgent conservation challenge and introduce a novel antiviral strategy with broad implications for herpesvirus vaccine development.


  • Open Access

    Evaluation of a multiantigen mRNA vaccine against EEHV1A in Asian elephants

    by Lauren Farris, Jessica Watts, Jeroen Pollet, Christine Molter, Sarah Cannizzo, Michael Wenninger, Jessica Heinz, Rebecca Eddy, Jessica Emerson, Dewey Maddox, et al.

    Elephant endotheliotropic herpesvirus (EEHV) is endemic in Asian elephants and can cause fatal hemorrhagic disease (HD) in juveniles, with calves aged 1–8 years being most vulnerable, particularly following the decline of maternal antibodies. Current supportive treatments, which commonly include fluids, plasma infusions, and human anti-herpesvirus drugs, are not consistently effective, highlighting the urgent need for preventative strategies. To address this challenge, we generated an EEHV1A multi-antigen mRNA vaccine targeting four conserved herpesvirus entry proteins (gB, gH, gL, and gO), which elicited robust humoral and cellular immune responses in mice without adverse effects. Based on these preclinical findings, a vaccine trial was conducted in nine Asian elephants, comprising three seropositive and six seronegative individuals. Animals received up to four 400 μg doses intramuscularly 3 weeks apart, with serum samples collected at baseline (day 0), post-booster (day 42), and monthly through day 192. Seropositive elephants demonstrated anamnestic responses with increased antibody levels to all four vaccine antigens individually. Seronegative elephants responded more robustly to gH and gL versus variable responses to gB and gO. Enzyme-linked immunosorbent assays (ELISAs) detecting the gH/gL/gO trimer indicate sustained antibody level increases in both sero-positive and sero-negative groups, persisting up to 192 days post-vaccination in seropositive elephants. Notably, post-vaccine titers against the trimer in some seronegative elephants reached up to 50% of baseline levels observed in EEHV-experienced subadult and adult elephants. These findings represent a critical advancement toward an effective EEHV1A vaccine to reduce HD mortality and support Asian elephant conservation efforts. IMPORTANCE: Elephant endotheliotropic herpesvirus (EEHV) causes fatal hemorrhagic disease in 65% of infected juvenile Asian elephants, critically threatening this endangered species with fewer than 50,000 individuals remaining globally. This study demonstrates the first successful mRNA vaccine application in elephants, targeting EEHV1A glycoproteins essential for viral attachment and entry. The vaccine elicited sustained antibody responses for up to 6 months in both EEHV-naive and previously infected elephants, with post-vaccination levels in some seronegative animals reaching 50% of those in chronically infected adults. These immunological data provide a critical baseline understanding of protective immunity, as demonstrated in a companion case report where two vaccinated elephants from this cohort survived subsequent wild-type EEHV1A infection without hemorrhagic disease. This work establishes mRNA vaccination as a viable conservation strategy, providing a scalable platform adaptable for other EEHV subtypes and representing a crucial advancement toward preventing EEHV mortality in endangered elephants.


  • Open Access

    Correction: Watts et al. Multi-Antigen Elephant Endotheliotropic Herpesvirus (EEHV) mRNA Vaccine Induces Humoral and Cell-Mediated Responses in Mice. Vaccines 2024, 12, 1429

    by Jessica R. Watts, Jennifer L. Spencer Clinton, Jeroen Pollet, Rongsheng Peng, Jie Tan, Paul D. Ling

    The authors would like to make the following corrections to this published paper

  • Open Access

    Multi-Antigen Elephant Endotheliotropic Herpesvirus (EEHV) mRNA Vaccine Induces Humoral and Cell-Mediated Responses in Mice

    by Jessica R. Watts, Jennifer L. Spencer Clinton, Jeroen Pollet, Rongsheng Peng, Jie Tan, Paul D. Ling

    Background/Objectives: Elephant endotheliotropic herpesvirus (EEHV) causes lethal hemorrhagic disease (HD) in Asian and African elephants in human care and the wild. It is the leading cause of death for young Asian elephants in North American and European zoos despite sensitive diagnostic tests and improved treatments. Thus, there is a critical need to develop an effective vaccine to prevent severe illness and reduce mortality from EEHV-HD. We generated a multi-antigenic EEHV mRNA vaccine to address this need that encodes the EEHV1A-subtype glycoproteins gB, gH, gL, and gO. These conserved proteins are the entry machinery for several herpesviruses in the betaherpesvirus subfamily and elicit humoral and cellular immunity in naturally infected elephants. Methods: Outbred CD-1 mice were vaccinated with two doses of an mRNA vaccine comprising modified EEHV1A gB, gH, gL, and gO mRNAs encapsulated into lipid nanoparticles. Humoral and T-cell immunity was assessed three weeks after the first dose or three weeks after the booster dose using luciferase immunoprecipitation system assays and flow cytometry, respectively. Results: The CD-1 mice vaccinated once had detectable antibody titers against gB, gH, and gL that increased significantly three weeks after a booster dose. Activated CD4+ and CD8+ T cells secreting cytokines associated with a TH1 response were induced against all four glycoproteins. No adverse effects were observed following one or two doses of the vaccine. Conclusions: We found that gB, gH, gL, and gO as a multivalent vaccine stimulated robust humoral and cell-mediated immunity. This is a critical step for moving this candidate EEHV1A mRNA vaccine into clinical trials in Asian elephants.


  • The EEHV1A gH/gL complex elicits humoral and cell-mediated immune responses in mice

    by Jennifer L. Spencer Clinton, Tabitha E. Hoornweg, Jie Tan, Rongsheng Peng, Willem Schaftenaar, Victor P.M.G. Rutten, Cornelis A.M. de Haan, Paul D. Ling


  • Open Access

    EEHV1A glycoprotein B subunit vaccine elicits humoral and cell-mediated immune responses in mice

    by Jennifer L. Spencer Clinton, Tabitha E. Hoornweg, Jie Tan, Rongsheng Peng, Willem Schaftenaar, Victor P.M.G. Rutten, Cornelis A.M. de Haan, Paul D. Ling


  • Open Access

    Modified vaccinia Ankara expressing EEHV1A glycoprotein B elicits humoral and cell-mediated immune responses in mice

    by Taylor Pursell, Jennifer L. Spencer Clinton, Jie Tan, Rongsheng Peng, Paul D. Ling

    Elephant endotheliotropic herpesvirus (EEHV) can cause lethal hemorrhagic disease (EEHV-HD) in Asian elephants and is the largest cause of death in captive juvenile Asian elephants in North America and Europe. EEHV-HD also has been documented in captive and wild elephants in their natural range countries. A safe and effective vaccine to prevent lethal EEHV infection would significantly improve conservation efforts for this endangered species. Recent studies from our laboratory suggest that EEHV morbidity and mortality are often associated with primary infection. Therefore, we aim to generate a vaccine, particularly for EEHV1 naïve animals, with the goal of preventing lethal EEHV-HD. To address this goal, we generated a Modified Vaccinia Ankara (MVA) recombinant virus expressing a truncated form of glycoprotein B (gBΔfur731) from EEHV1A, the strain associated with the majority of lethal EEHV cases. Vaccination of CD-1 mice with this recombinant virus induced robust antibody and polyfunctional T cell responses significantly above mice inoculated with wild-type MVA. Although the vaccine-induced T cell response was mainly observed in CD8+ T cell populations, the CD4+ T cell response was also polyfunctional. No adverse responses to vaccination were observed. Overall, our data demonstrates that MVA-gBΔfur731 stimulates robust humoral and cell-mediated responses, supporting its potential translation for use in elephants.


  • Open Access

    Primary Infection May Be an Underlying Factor Contributing to Lethal Hemorrhagic Disease Caused by Elephant Endotheliotropic Herpesvirus 3 in African Elephants ( Loxodonta africana )

    by Taylor Pursell, Jennifer L. Spencer Clinton, Jie Tan, Rongsheng Peng, Xiang Qin, Harshavardhan Doddapaneni, Vipin Menon, Zeineen Momin, Kavya Kottapalli, Lauren Howard, et al.

    Prior to 2019, only five cases of clinical disease from EEHV infection among African elephants had been documented. Since 2019, there have been at least seven EEHV-HD cases in North American zoos, resulting in three fatalities, all associated with EEHV3.


  • Open Access

    Lethal Hemorrhagic Disease and Clinical Illness Associated with Elephant Endotheliotropic Herpesvirus 1 Are Caused by Primary Infection: Implications for the Detection of Diagnostic Proteins

    by Angela Fuery, Taylor Pursell, Jie Tan, Rongsheng Peng, Peter D. Burbelo, Gary S. Hayward, Paul D. Ling

    Whether clinical illness and deaths associated with elephant endotheliotropic herpesvirus (EEHV) infection result from primary infection or reactivation of latent virus is a longstanding question in the field. By applying a relatively new assay, the luciferase immunoprecipitation system (LIPS), combined with the genomic sequences of the viruses, we gained the insights and tools needed to resolve this issue. Our EEHV1-specific LIPS assay should be useful for assessing the vulnerability of elephant calves to infection with different EEHVs and evaluating antibody responses to anti-EEHV vaccines. A significant proportion of the Asian elephant population is under some form of human care. Hence, the ability to screen for EEHV immune status in elephant calves should have a major impact on the management of these animals worldwide.


  • Open Access

    Asian Elephant T Cell Responses to Elephant Endotheliotropic Herpesvirus

    by Angela Fuery, Ann M. Leen, Rongsheng Peng, Matthew C. Wong, Hao Liu, Paul D. Ling

    Elephant endotheliotropic herpesvirus (EEHV) can cause lethal hemorrhagic disease in juvenile Asian elephants, an endangered species. One hypothesis to explain this vulnerability of some juvenile elephants is that they fail to mount an effective T cell response to the virus. To our knowledge, there have been no studies of Asian elephant T cell responses to EEHV. To address this deficiency, we validated the gamma interferon (IFN-γ) enzyme-linked immunospot assay for tracking antigen-directed T cell activity by monitoring rabies-specific responses in vaccinated elephants. In addition, we generated monoclonal antibodies to Asian elephant CD4 and CD8 to facilitate phenotypic T cell profiling. Using these tools, we screened healthy elephants with a history of EEHV infection for reactivity against nine EEHV proteins whose counterparts in other herpesviruses are known to induce T cell responses in their natural hosts. We identified glycoprotein B (gB) and the putative regulatory protein E40 as the most immunogenic T cell targets (IFN-γ responses in five of seven elephants), followed by the major capsid protein (IFN-γ responses in three of seven elephants). We also observed that IFN-γ responses were largely from CD4 + T cells. We detected no activity against the predicted major immediate early (E44) and large tegument (E34) proteins, both immunodominant T cell targets in humans latently infected with cytomegalovirus. These studies identified EEHV-specific T cells in Asian elephants for the first time, lending insight into the T cell priming that might be required to protect against EEHV disease, and will guide the design of effective vaccine strategies. IMPORTANCE Endangered Asian elephants are facing many threats, including lethal hemorrhagic disease from elephant endotheliotropic herpesvirus (EEHV). EEHV usually establishes chronic, benign infections in mature Asian elephants but can be lethal to juvenile elephants in captivity and the wild. It is the leading cause of death in captive Asian elephants in North America and Europe. Despite the availability of sensitive tests and protocols for treating EEHV-associated illness, these measures are not always effective. The best line of defense would be a preventative vaccine. We interrogated normal healthy elephants previously infected with EEHV for T cell responses to nine EEHV proteins predicted to induce cellular immune responses. Three proteins elicited IFN-γ responses, suggesting their potential usefulness as vaccine candidates. Our work is the first to describe T cell responses to a member of the proposed fourth subfamily of mammalian herpesviruses, the Deltaherpesvirinae , within a host species in the clade Afrotheria. An EEHV vaccine would greatly contribute to the health care of Asian and African elephants that are also susceptible to this disease.